Patients were randomized to stay on their treatment at the time of enrollment or to be switched to MIRCERA in order to maintain stable haemoglobin levels.
Patsiendid randomiseeriti jätkama kasutatavat ravi või viidi üle MIRCERA- ravile, et saavutada stabiilne hemoglobiinisisaldus.